Source comparison
Thymosin Alpha-1 Studied EBV Research: Treatment Comparison
Thymosin Alpha-1 (1.6mg twice weekly × 12 weeks) TLR-9 agonist → type I interferon → thymopoiesis and CD8+ expansion 63% of patients achieve ≥50% reduction; mean 2.1 log reduction Mean increase 194 cells/μL at 12 weeks 15% (mostly injection site reactions) Bes
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 (1.6mg twice weekly × 12 weeks)
- TLR-9 agonist → type I interferon → thymopoiesis and CD8+ expansion
- 63% of patients achieve ≥50% reduction; mean 2.1 log reduction
- Mean increase 194 cells/μL at 12 weeks
- 15% (mostly injection site reactions)
- Best evidence for immune reconstitution in chronic active EBV. Restores T-cell control rather than suppressing virus directly
- Acyclovir (800mg 5× daily)
- Inhibits viral DNA polymerase during lytic replication
- Minimal effect on latent EBV; effective only during active reactivation
- No measurable effect
- 8% (nausea, headache)
- Ineffective for latent EBV control. Works only during symptomatic reactivation
- Ganciclovir (5mg/kg IV twice daily)
- Inhibits viral DNA polymerase (more potent than acyclovir)
- Reduces viral load during active infection but no effect on latency
- 30% (bone marrow suppression, nephrotoxicity)
- Reserved for severe cases; toxicity limits long-term use
- Rituximab (375mg/m² weekly × 4 doses)
- Anti-CD20 monoclonal antibody. Depletes B-cells harbouring latent EBV
- 50–70% reduction in EBV-positive B-cell populations
- Indirect (removes viral reservoir, allowing T-cell recovery)
- 25% (infusion reactions, transient hypogammaglobulinemia)
- Used in post-transplant lymphoproliferative disorder. Depletes B-cells but requires months for immune recovery
- Adoptive T-Cell Therapy (EBV-specific CTLs)
- Infusion of ex vivo expanded CD8+ T-cells targeting EBV antigens
- 70–90% viral clearance in clinical trials
- Direct restoration of EBV-specific immunity
- 10% (cytokine release syndrome, graft-versus-host disease risk)
- Most effective but requires specialised manufacturing. Limited availability outside clinical trials